Cyanocobalamin vs methylcobalamin vs hydroxocobalamin: does the B12 form matter?

"Methylcobalamin is the active form your body actually uses." That sentence sells a lot of supplements. The biochemistry is more nuanced — all three commercial cobalamins enter the same intracellular pool, but they differ in stability, retention, and the clinical situations in which one is preferred.

What each form actually is

Cyanocobalamin is a synthetic form with a cyanide group attached to the central cobalt atom. After uptake, intracellular reductases cleave the cyanide (released in physiologically trivial micromole-per-day amounts) and convert the cobalamin to the two active coenzymes: methylcobalamin (cytosolic, supports methionine synthase) and adenosylcobalamin (mitochondrial, supports methylmalonyl-CoA mutase). Methylcobalamin and hydroxocobalamin are alternative supplemental forms; hydroxocobalamin has a hydroxyl group at the upper axial position and is the form used in cyanide-poisoning kits at 5–10 g intravenous doses. Adenosylcobalamin is rarely sold orally because it is light-sensitive and unstable in the gut.

Bioavailability and retention head-to-heads

For parenteral injection, hydroxocobalamin is retained substantially better than cyanocobalamin — roughly 90 percent retention versus 45 percent after a 1 mg intramuscular dose at 48 hours, according to the classic 1971 Adams kinetic study and confirmed in modern reviews (PMID: 24222693).¹ This is why UK NHS practice uses hydroxocobalamin 1 mg every 2–3 months for pernicious anaemia maintenance, while US practice still uses cyanocobalamin monthly. Oral cyanocobalamin at 1,000–2,000 mcg/day is effective for B12 repletion even in pernicious anaemia because passive diffusion accounts for ~1 percent absorption, bypassing intrinsic factor (PMID: 16027407).² Methylcobalamin and cyanocobalamin oral bioavailability and serum response are similar at supplemental doses in healthy subjects (PMID: 21261520).³

The "skip the conversion" argument

The marketing claim that methylcobalamin is preferable because it skips the conversion step is technically true but rarely consequential. Cobalamin-handling defects that affect this conversion (cblA, cblB, cblC, cblG — collectively the inborn errors of cobalamin metabolism) are rare and present in early childhood. The 2016 Society for Inherited Metabolic Disorders guideline assigns adenosylcobalamin and hydroxocobalamin specifically for cblA and cblB defects, where cyanocobalamin is contraindicated (PMID: 27500232).⁴ In adults without these defects, the cellular machinery converts all three forms efficiently.

When each form fits

Cyanocobalamin: cheapest, most stable, regulatory default. Reasonable for routine oral repletion in adults without specific contraindications. Avoid in advanced renal failure where cyanide clearance is impaired and Leber's hereditary optic neuropathy, where cyanocobalamin has been associated with disease progression (PMID: 12091188).⁵ Methylcobalamin: more expensive, similar oral pharmacokinetics, modest theoretical advantage in diabetic neuropathy where high-dose 1,500 mcg/day improved nerve-conduction velocity in small Japanese trials (PMID: 24139800).⁶ Hydroxocobalamin: parenteral first choice in most national guidelines for B12 deficiency anaemia and the only form labeled for cyanide poisoning.

Megadose oral B12 in pernicious anaemia

A 2018 Cochrane review concluded that oral high-dose cyanocobalamin (1,000-2,000 mcg/day) is non-inferior to intramuscular B12 for haematologic and neurologic outcomes in pernicious anaemia, given adherence (PMID: 28244064).⁷ The British Society for Haematology 2022 guideline supports oral therapy as first line for many adults with B12 deficiency without severe neurologic symptoms (PMID: 35275397).⁸

Practical takeaways

For a routine vegan or post-bariatric oral B12 supplement, cyanocobalamin 1,000 mcg/day is the most cost-effective evidence-based default. Methylcobalamin is reasonable but rarely necessary. Hydroxocobalamin injections remain the first parenteral choice in most national guidelines. The genuine "form matters" cases are the rare inborn cobalamin defects, Leber's hereditary optic neuropathy, and active cyanide exposure — not garden-variety dietary deficiency.